{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:19Z","timestamp":1792724779503,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T00:00:00Z","timestamp":1446508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T00:00:00Z","timestamp":1446508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/leu.2015.311","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T07:42:07Z","timestamp":1446536527000},"page":"701-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells"],"prefix":"10.1038","volume":"30","author":[{"given":"K","family":"Pinz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Golightly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Jares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G W","family":"Zieve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Hagag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E","family":"Firor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,3]]},"reference":[{"key":"BFleu2015311_CR1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1535370215584936","volume":"240","author":"AE Firor","year":"2015","unstructured":"Firor AE, Jares A, Ma Y . From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med 2015; 240: 1087\u20131098.","journal-title":"Exp Biol Med"},{"key":"BFleu2015311_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/imr.12243","volume":"263","author":"S Gill","year":"2015","unstructured":"Gill S, June CH . Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 2015; 263: 68\u201389.","journal-title":"Immunol Rev"},{"key":"BFleu2015311_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fonc.2013.00138","volume":"3","author":"AP Skarbnik","year":"2013","unstructured":"Skarbnik AP, Burki M, Pro B . Peripheral T-cell lymphomas: a review of current approaches and hopes for the future. Front Oncol 2013; 3: 138.","journal-title":"Front Oncol"},{"key":"BFleu2015311_CR4","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K . Peripheral T-cell lymphoma. Blood 2011; 117: 6756\u20136767.","journal-title":"Blood"},{"key":"BFleu2015311_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2249.1993.tb08176.x","volume":"93","author":"M Jonker","year":"1993","unstructured":"Jonker M, Slingerland W, Treacy G, van Eerd P, Pak KY, Wilson E et al. In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees. Clin Exp Immunol 1993; 93: 301\u2013307.","journal-title":"Clin Exp Immunol"},{"key":"BFleu2015311_CR6","doi-asserted-by":"publisher","first-page":"R177","DOI":"10.1186\/ar3502","volume":"13","author":"H Scheerens","year":"2011","unstructured":"Scheerens H, Su Z, Irving B, Townsend MJ, Zheng Y, Stefanich E et al. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Arthritis Res Ther 2011; 13: R177.","journal-title":"Arthritis Res Ther"},{"key":"BFleu2015311_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/art.1780370610","volume":"37","author":"LW Moreland","year":"1994","unstructured":"Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ . Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. Arthritis Rheum 1994; 37: 834\u2013838.","journal-title":"Arthritis Rheum"},{"key":"BFleu2015311_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/BF02283116","volume":"11","author":"D Wendling","year":"1992","unstructured":"Wendling D, Racadot E, Morel-Fourrier B, Wijdenes J . Treatment of rheumatoid arthritis with anti CD4 monoclonal antibody. Open study of 25 patients with the B-F5 clone. Clin Rheumatol 1992; 11: 542\u2013547.","journal-title":"Clin Rheumatol"},{"key":"BFleu2015311_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-3083.1992.tb03102.x","volume":"36","author":"EH Choy","year":"1992","unstructured":"Choy EH, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS . Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 1992; 36: 291\u2013298.","journal-title":"Scand J Immunol"},{"key":"BFleu2015311_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/art.1780340202","volume":"34","author":"G Horneff","year":"1991","unstructured":"Horneff G, Burmester GR, Emmrich F, Kalden JR . Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991; 34: 129\u2013140.","journal-title":"Arthritis Rheum"},{"key":"BFleu2015311_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410360210","volume":"36","author":"JW Lindsey","year":"1994","unstructured":"Lindsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L . Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 1994; 36: 183\u2013189.","journal-title":"Ann Neurol"},{"issue":"Pt 1","key":"BFleu2015311_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1212\/WNL.44.3_Part_1.413","volume":"44","author":"JW Lindsey","year":"1994","unstructured":"Lindsey JW, Hodgkinson S, Mehta R, Siegel RC, Mitchell DJ, Lim M et al. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994; 44 (Pt 1): 413\u2013419.","journal-title":"Neurology"},{"key":"BFleu2015311_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1006\/jaut.1993.1063","volume":"6","author":"E Racadot","year":"1993","unstructured":"Racadot E, Rumbach L, Bataillard M, Galmiche J, Henlin JL, Truttmann M et al. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients. J Autoimmun 1993; 6: 771\u2013786.","journal-title":"J Autoimmun"},{"issue":"Pt 1","key":"BFleu2015311_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0190-9622(96)80119-8","volume":"34","author":"JC Prinz","year":"1996","unstructured":"Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G . Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 1996; 34 (Pt 1): 244\u2013252.","journal-title":"J Am Acad Dermatol"},{"key":"BFleu2015311_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0140-6736(91)90465-2","volume":"338","author":"JF Nicolas","year":"1991","unstructured":"Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP . CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321.","journal-title":"Lancet"},{"key":"BFleu2015311_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1067\/mjd.2000.107945","volume":"43","author":"AB Gottlieb","year":"2000","unstructured":"Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43: 595\u2013604.","journal-title":"J Am Acad Dermatol"},{"key":"BFleu2015311_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archderm.139.11.1433","volume":"139","author":"L Skov","year":"2003","unstructured":"Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GB et al. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol 2003; 139: 1433\u20131439.","journal-title":"Arch Dermatol"},{"key":"BFleu2015311_CR18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","volume":"87","author":"S Knox","year":"1996","unstructured":"Knox S, Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893\u2013899.","journal-title":"Blood"},{"key":"BFleu2015311_CR19","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","volume":"109","author":"YH Kim","year":"2007","unstructured":"Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655\u20134662.","journal-title":"Blood"},{"key":"BFleu2015311_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","volume":"150","author":"F d'Amore","year":"2010","unstructured":"d'Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010; 150: 565\u2013573.","journal-title":"Br J Haematol"},{"key":"BFleu2015311_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1385\/MO:22:2:191","volume":"22","author":"H Hagberg","year":"2005","unstructured":"Hagberg H, Pettersson M, Bjerner T, Enblad G . Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol 2005; 22: 191\u2013194.","journal-title":"Med Oncol"},{"key":"BFleu2015311_CR22","doi-asserted-by":"publisher","first-page":"9945","DOI":"10.1158\/0008-5472.CAN-07-1148","volume":"67","author":"DA Rider","year":"2007","unstructured":"Rider DA, Havenith CE, de Ridder R, Schuurman J, Favre C, Cooper JC et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res 2007; 67: 9945\u20139953.","journal-title":"Cancer Res"},{"key":"BFleu2015311_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-immunol-032713-120136","volume":"32","author":"MV Maus","year":"2014","unstructured":"Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH . Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014; 32: 189\u2013225.","journal-title":"Annu Rev Immunol"},{"key":"BFleu2015311_CR24","doi-asserted-by":"publisher","first-page":"969","DOI":"10.4049\/jimmunol.173.2.969","volume":"173","author":"AL Marzo","year":"2004","unstructured":"Marzo AL, Vezys V, Klonowski KD, Lee SJ, Muralimohan G, Moore M et al. Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol 2004; 173: 969\u2013975.","journal-title":"J Immunol"},{"key":"BFleu2015311_CR25","doi-asserted-by":"publisher","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila ML, Kloss CC, Gunset G, Sadelain M . CD19 CAR-targeted T cells induce long-term remission and B Cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 2013; 8: e61338.","journal-title":"PLoS One"},{"key":"BFleu2015311_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","volume":"119","author":"S Terakura","year":"2012","unstructured":"Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR . Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 2012; 119: 72\u201382.","journal-title":"Blood"},{"key":"BFleu2015311_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e318270dec7","volume":"35","author":"X Wang","year":"2012","unstructured":"Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 2012; 35: 689\u2013701.","journal-title":"J Immunother"},{"key":"BFleu2015311_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1086\/380802","volume":"189","author":"DR Kuritzkes","year":"2004","unstructured":"Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189: 286\u2013291.","journal-title":"J Infect Dis"},{"key":"BFleu2015311_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0300-483X(02)00002-1","volume":"172","author":"L Boon","year":"2002","unstructured":"Boon L, Holland B, Gordon W, Liu P, Shiau F, Shanahan W et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 2002; 172: 191\u2013203.","journal-title":"Toxicology"},{"key":"BFleu2015311_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/aid.1997.13.933","volume":"13","author":"KA Reimann","year":"1997","unstructured":"Reimann KA, Lin W, Bixler S, Browning B, Ehrenfels BN, Lucci J et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997; 13: 933\u2013943.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"BFleu2015311_CR31","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/cr.2013.40","volume":"23","author":"X Meng","year":"2013","unstructured":"Meng X, Su RJ, Baylink DJ, Neises A, Kiroyan JB, Lee WY et al. Rapid and efficient reprogramming of human fetal and adult blood CD34+ cells into mesenchymal stem cells with a single factor. Cell Res 2013; 23: 658\u2013672.","journal-title":"Cell Res"},{"key":"BFleu2015311_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3378\/027.081.0104","volume":"81","author":"AG Nikitin","year":"2009","unstructured":"Nikitin AG, Kochkin IT, June CM, Willis CM, McBain I, Videiko MY . Mitochondrial DNA sequence variation in the Boyko, Hutsul, and Lemko populations of the Carpathian highlands. Hum Biol 2009; 81: 43\u201358.","journal-title":"Hum Biol"},{"key":"BFleu2015311_CR33","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.1128\/JVI.72.11.9054-9060.1998","volume":"72","author":"SG Kitchen","year":"1998","unstructured":"Kitchen SG, Korin YD, Roth MD, Landay A, Zack JA . Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol 1998; 72: 9054\u20139060.","journal-title":"J Virol"},{"key":"BFleu2015311_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1084\/jem.187.7.1139","volume":"187","author":"LP Yang","year":"1998","unstructured":"Yang LP, Riley JL, Carroll RG, June CH, Hoxie J, Patterson BK et al. Productive infection of neonatal CD8+ T lymphocytes by HIV-1. J Exp Med 1998; 187: 1139\u20131144.","journal-title":"J Exp Med"},{"key":"BFleu2015311_CR35","doi-asserted-by":"publisher","first-page":"e82742","DOI":"10.1371\/journal.pone.0082742","volume":"8","author":"LE Budde","year":"2013","unstructured":"Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One 2013; 8: e82742.","journal-title":"PLoS One"},{"key":"BFleu2015311_CR36","first-page":"981","volume":"28","author":"V Ambrosini","year":"2008","unstructured":"Ambrosini V, Quarta C, Zinzani PL, Fini M, Giavaresi G, Torricelli P et al. 18F-FDG small animal PET for early detection of human anaplastic large cells lymphoma xenograft in immunocompromised mice. Anticancer Res 2008; 28: 981\u2013987.","journal-title":"Anticancer Res"},{"key":"BFleu2015311_CR37","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009; 32: 689\u2013702.","journal-title":"J Immunother"},{"key":"BFleu2015311_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/0090-1229(87)90040-7","volume":"45","author":"C Pitzalis","year":"1987","unstructured":"Pitzalis C, Kingsley G, Murphy J, Panayi G . Abnormal distribution of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint. Clin Immunol Immunopathol 1987; 45: 252\u2013258.","journal-title":"Clin Immunol Immunopathol"},{"key":"BFleu2015311_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000060506","volume":"2","author":"H Schulze-Koops","year":"2000","unstructured":"Schulze-Koops H, Lipsky PE . Anti-CD4 monoclonal antibody therapy in human autoimmune diseases. Curr Dir Autoimmun 2000; 2: 24\u201349.","journal-title":"Curr Dir Autoimmun"},{"key":"BFleu2015311_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2249.2003.02381.x","volume":"135","author":"D Pohlers","year":"2004","unstructured":"Pohlers D, Nissler K, Frey O, Simon J, Petrow PK, Kinne RW et al. Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen-induced arthritis: influence on T helper cell activation. Clin Exp Immunol 2004; 135: 409\u2013415.","journal-title":"Clin Exp Immunol"},{"key":"BFleu2015311_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1212\/WNL.49.2.351","volume":"49","author":"BW van Oosten","year":"1997","unstructured":"van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997; 49: 351\u2013357.","journal-title":"Neurology"},{"key":"BFleu2015311_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2014","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2014; 385: 517\u2013528.","journal-title":"Lancet"},{"key":"BFleu2015311_CR43","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509\u20131518.","journal-title":"N Engl J Med"},{"key":"BFleu2015311_CR44","first-page":"221","volume":"59","author":"D Wofsy","year":"1993","unstructured":"Wofsy D . Treatment of murine lupus with anti-CD4 monoclonal antibodies. Immunol Ser 1993; 59: 221\u2013236.","journal-title":"Immunol Ser"},{"key":"BFleu2015311_CR45","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.4049\/jimmunol.149.9.3083","volume":"149","author":"K Connolly","year":"1992","unstructured":"Connolly K, Roubinian JR, Wofsy D . Development of murine lupus in CD4-depleted NZB\/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol 1992; 149: 3083\u20133088.","journal-title":"J Immunol"},{"key":"BFleu2015311_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1189\/jlb.1010579","volume":"90","author":"H Yu","year":"2011","unstructured":"Yu H, Tawab-Amiri A, Dzutsev A, Sabatino M, Aleman K, Yarchoan R et al. IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. J Leukoc Biol 2011; 90: 205\u2013214.","journal-title":"J Leukoc Biol"},{"key":"BFleu2015311_CR47","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH . Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123: 2625\u20132635.","journal-title":"Blood"},{"key":"BFleu2015311_CR48","first-page":"402","volume":"3","author":"I Barao","year":"2012","unstructured":"Barao I . The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses. Front Immunol 2012; 3: 402.","journal-title":"Front Immunol"},{"key":"BFleu2015311_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1128\/CVI.13.2.227-234.2006","volume":"13","author":"A Sun","year":"2006","unstructured":"Sun A, Wei H, Sun R, Xiao W, Yang Y, Tian Z . Human interleukin-15 improves engraftment of human T cells in NOD-SCID mice. Clin Vaccine Immunol 2006; 13: 227\u2013234.","journal-title":"Clin Vaccine Immunol"},{"key":"BFleu2015311_CR50","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.","journal-title":"Sci Transl Med"},{"key":"BFleu2015311_CR51","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/mt.2014.28","volume":"22","author":"A Globerson-Levin","year":"2014","unstructured":"Globerson-Levin A, Waks T, Eshhar Z . Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther 2014; 22: 1029\u20131038.","journal-title":"Mol Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015311","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T18:31:35Z","timestamp":1692124295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFleu2015311"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.311","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,3]]},"assertion":[{"value":"29 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yupo Ma is a founder and Chairman of iCell Gene Therapeutics, LLC. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}